Top Back to top

EBMT trial demonstrates improvements in immunosuppressive treatment of patients with Severe Aplastic Anemia

Severe Aplastic Anaemia Working Party (SAAWP)

Over the past three decades, efforts to improve the results of standard treatment for patients with Severe Aplastic Anemia have been largely unsuccessful. The phase III RACE trial, sponsored by the EBMT, published on January 6, 2022, by the New England Journal of Medicine now demonstrates that adding Eltrombopag to standard immunosuppressive treatment is safe and increases response rates in patients with this rare, yet potentially fatal disease.